tenalisib
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Jul 18, 2018 (NCT03471351)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1- Mol. weight
- 415.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297584 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06189209 | Phase 2 | Mar 4, 2024 | Incozen Therapeutics Pvt Ltd, Rhizen Pharmaceuticals SA |
| NCT05239910 | Phase 2 | Jan 31, 2023 | Rhizen Pharmaceuticals SA |
| NCT05021900 | Phase 2 | Oct 13, 2021 | Rhizen Pharmaceuticals SA |
| NCT04204057 | Phase 2 | Nov 28, 2019 | Rhizen Pharmaceuticals SA |
| NCT03770000 | Phase 1/Phase 2 (Phase 2) | Mar 12, 2019 | Rhizen Pharmaceuticals SA |
| NCT03711604 | Phase 1/Phase 2 (Phase 2) | Nov 28, 2018 | Rhizen Pharmaceuticals SA |
| NCT03711578 | Phase 2 | Nov 25, 2018 | Rhizen Pharmaceuticals SA |
| NCT03471351 | Phase 1/Phase 2 (Phase 2) | Jul 18, 2018 | Rhizen Pharmaceuticals SA |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rhizen Pharmaceuticals SA | For profit | 8 | 8 | 1 | 2018 |
| Incozen Therapeutics Pvt Ltd | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1